Neuroprotective Activity of Thioctic Acid in Central Nervous System Lesions Consequent to Peripheral Nerve Injury
Figure 10
8-Oxo-dG immunoreactivity in the cerebral cortex (layer VI) of the different animal groups investigated (a) and densitometric analysis of the intensity of immunoreaction (histogram). (A) WKY control Sham-operated rats, (B) control Sham-operated SHRs, (C) control CCI SHRs, (D) CCI SHRs treated with ()-thioctic acid 250 μmol/kg/day, (E) CCI SHRs treated with ()-thioctic acid 125 μmol/kg/day, (F) CCI SHRs treated with (+)-thioctic acid 125 μmol/kg/day, (G) CCI SHRs treated with (−)-thioctic acid 125 μmol/kg/day, and (H) CCI SHRs treated with pregabalin 300 μmol/kg/day (H). * versus WKY control rats; *** versus control CCI SHR. Calibration bar: 10 μm.
